Visterra is a biologics research and early-stage clinical development company developing therapies for patients with immune-mediated and other hard-to-treat diseases.
Ready to make a meaningful impact?
At Visterra, we champion innovation, teamwork, and perseverance.
You’ll be challenged and empowered to make meaningful impacts as a member of a collaborative, high-performing, agile team.
Our approach is unique.
At Visterra, we believe innovative technologies and approaches are critical to developing novel therapeutics – from cutting-edge computational, AI, and experimental research methods to agile preclinical development, reliable manufacturing, and creative trial designs.
Immunoglobulin A
Nephropathy (IgAN)
Sibeprenlimab (VIS649) is an investigational humanized IgG2 monoclonal antibody being evaluated for the treatment of IgA nephropathy (IgAN), a chronic, progressive kidney disease.
Schachter, Asher
“The rare combination of people, platform, pipeline, and commitment to patients is what drives my sense of purpose daily at Visterra. Particularly exciting to me is the translational medicine space, in which we are the first to bridge the science with patients in need.” – Asher Schachter, Vice President, Translational Medicine
“The rare combination of people, platform, pipeline, and commitment to patients is what drives my sense of purpose daily at Visterra. Particularly exciting to me is the translational medicine space, in which we are the first to bridge the science with patients in need.”
– Asher Schachter, Vice President, Translational Medicine
Committed to extending and improving the lives of people afflicted with immune-mediated diseases.
Our team is fueled by curiosity, guided by the scientific method and innovative clinical research strategies, culminating in novel therapies engineered to augment and surpass standard of care.
